Pacira Pharmaceuticals, Inc. company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Once the injectables subsidiary of drug-delivery company SkyePharma PLC, Pacira was bought out in 2007 by an investor group led by MPM Capital, OrbiMed, HBM Bioventures, and Sanderling Ventures.

Astex Therapeutics (formerly Astex Technology) is working on Pyramids, but on a much, much smaller scale than the Egyptians did. Astex Therapeutics Limited company's Pyramid is a fragment-based drug discovery platform that utilizes X-ray crystallography to develop small molecule drugs. Astex is using the Pyramid platform to develop new therapies for Alzheimer's disease, numerous types of cancers, and chronic inflammation. The company relies in part on a large group of investors for funding. Some of its main investors include Oxford Biosciences, Advent International, Apax, Bayer Schering, and Johnson & Johnson. Astex is collaborating with Novartis andJanssen Pharmaceutica on drugs for the treatment of cancer.

Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey. Cambrex Corporation, a life sciences company, provides products and services to develop and commercialize active pharmaceutical ingredients and advanced intermediates. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, and other custom chemicals derived from organic chemistry. The company sells its products through direct sales and independent agents to pharmaceutical and generic drug companies worldwide.

The Mentholatum Company's best-known products, Mentholatum Deep Heating Rub, but they can probably find another of the company's bestsellers in their medicine cabinets -- Oxy Pads. The Mentholatum Company, a subsidiary of ROHTO Pharmaceutical, makes OTC products to relieve a variety of common ailments, including acne, cold sores, aches and pains, and chest congestion. In addition to the Oxy and Mentholatum brands, the firm sells its products under the WellPatch, Rohto, Fletcher's, Red Cross, Natural Ice, and Softlips monikers. ROHTO's Mentholatum companies have operations in more than a dozen countries and sells products in more than 150 countries.

EraGen Biosciences, Inc. company is developing nucleic databases and other tools to help drug and diagnostics developers better use genomic information to streamline their R&D processes. Molecular clinical diagnostics, bioterrorism threat detection, and pesonalized medicine are other markets the company is pursuing. EraGen Biosciences has teamed with Luminex to distribute in vitro clinical diagnostics equipment that uses technology from both companies. Bayer HealthCare has licensed the company's MultiCode-PLx test for detecting cystic fibrosis.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts. Pressure BioSciences, Inc. (PBI) focuses on the development and commercialization of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. The company holds 13 U.S. and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI focuses on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications. It serves academic laboratories; government agencies; and biotechnology, pharmaceutical, and life science companies. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2004 as a result of change in business strategy.

Epigenomics AG is a Germany-based company engaged in the molecular diagnostics sector. It divides its products into two areas: solutions for early diagnosis of cancer and products for special diagnosis of cancer. Epigenomics AG produces and develops tests that help in the diagnosis of the colorectal, prostate and lung cancer. The Company also offers services in the field of identification and development of methylated deoxyribonucleic acid (DNA) biomarkers. Industry partners and the medical and life science communities can access the Company’s portfolio of filed patent families covering DNA methylation technologies and biomarkers, as well as its DNA methylation expertise through research products, biomarker services, in vitro diagnostics (IVD) development collaborations and licensing. It develops its solutions together with its commercial partners, Abbott Molecular Inc and Quest Diagnostics Inc. The Company has a subsidiary in the United States, Epigenomics, Inc.

Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company focuses on developing gene therapy treatments for oncology and neurotherapy. Its lead product,TroVax, is in testing for renal and colorectal cancer and is designed to stimulate the body's immune response to attack tumor cells. Another leading candidate, ProSavin, is in testing for treatment of Parkinson's disease. The company has several additional products in various stages of clinical development. Oxford BioMedica has awarded Sanofi-Aventis exclusive rights to develop and commercialize TroVax globally. The company's California-based BioMedica subsidiary handles its business development in North America and Asia.

Intercytex Limited company is developing cell-based treatments for skin and hair regeneration. Its ICX-TRC product candidate is injected just beneath the scalp to encourage new hair follicles to form. If the candidate wins approval in the US, Intercytex has lined up Bosley Medical Institute, a firm that manages hair transplant clinics across the US, to help distribute its regeneration product. Another product candidate, SHEF-1, could treat age-related macular degeneration. Its ICX-RHY launched in the UK in 2008 under the name Valvelta, as a cosmetic facial rejuvenation product injected transdermally to smoothe out wrinkles.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.